Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The H4-specific CD4+ T cells are the primary immunological effectors induced by the H4 (Ag85B-TB10.4) tuberculosis vaccine candidate. H4 is a recombinant fusion protein consisting of two major antigens from Mycobacterium tuberculosis: Ag85B (a mycolyltransferase) and TB10.4 (a member of the Esat-6 family). These T cells are characterized by a polyfunctional cytokine profile, typically producing interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2), which are critical for controlling intracellular mycobacterial infection. In clinical development, the H4 antigen is often formulated with adjuvants like IC31 to enhance the magnitude and durability of the CD4+ T cell response. While the T cells themselves are the biological readout of vaccine efficacy, the molecular target is the H4 fusion protein, which serves as the template for TCR recognition and immune memory induction.
Vaccine antigen that induces polyfunctional CD4+ T cell responses (IFN-gamma, TNF-alpha, IL-2) to provide protective immunity against Mycobacterium tuberculosis.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ag85B-TB10.4 fusion protein (H4) (H4).